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The p53 tumor suppressor protein, which is commonly mutated in human cancers, has been shown to
interact directly with virally encoded proteins from papillomavirus, adenovirus, and simian virus 40. The
disruption of p53 function may be required for efficient replication of certain viruses and may also play a role
in the development of virally induced malignancies. Infection with Epstein-Barr virus (EBV) has been
associated with the development of B-cell lymphomas and nasopharyngeal carcinoma. Here we show that the
EBV immediate-early protein, BZLF1 (Z), which is responsible for initiating the switch from latent to lytic
infection, can interact directly in vitro and in vivo with the tumor suppressor protein, p53. This interaction
requires the coiled-coil dimerization domain of the Z protein and the carboxy-terminal portion of p53.
Overexpression of wild-type p53 inhibits the ability of Z to disrupt viral latency. Likewise, Z inhibits
p53-dependent transactivation in lymphoid cells. The direct interaction between Z and p53 may play a role in
regulating the switch from latent to lytic viral infection.
The p53 tumor suppressor protein is an important negative
regulator of cell proliferation (38, 48, 63, 65) and is often
mutated in human cancers (26). The p53 protein interacts with
the viral E6 protein from certain cancer-associated strains of
human papillomavirus (36, 54, 68), the Elb protein of adeno-
virus (53, 72), and the large T antigen of papovaviruses (35,
53). The dysregulation of wild-type p53 function by viral
proteins is thought to play an important role in virus-induced
malignancy (37).
The interaction between viral proteins and p53 may also play
a role in the replication of certain viruses. The p53 protein
binds to the simian virus 40 origin of replication (3) and
inhibits the ability of large T antigen to mediate simian virus 40
replication in vitro (19, 67). In addition, p53 colocalizes with
the viral replication proteins in cells infected with herpes
simplex virus (70). These data suggest that p53 could poten-
tially regulate the replication of herpesviruses through direct
interaction with viral replicative proteins.
In this study, we have examined the ability of p53 to interact
with the Epstein-Barr virus (EBV) protein BZLF1 (Z), which
mediates lytic replication. EBV is a transforming virus in vitro,
and infection with EBV has been associated with the develop-
ment of both B-cell and epithelial cell malignancies in vivo
(reviewed in reference 44). EBV infection of B cells in vivo is
primarily latent, although productive infection can occur in
immunocompromised patients. The switch from latent to
productive infection is mediated by transcriptional activation
of the immediate-early Z gene (6, 52, 62). The Z gene product
(a member of the basic leucine zipper family) binds directly to
APl-like motifs as a homodimer and functions as a transcrip-
tional transactivator (5, 12, 14, 30, 34, 39, 49, 64). A number of
viral early promoters contain upstream Z-binding sites and are
activated upon expression of the Z gene product (6, 8, 12, 14,
25, 29, 49, 64). The Z protein also binds directly to the EBV
lytic origin of replication (ori-Lyt) and is required for lytic
replication (13, 55).
In this report, we demonstrate that Z can interact directly
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with the p53 protein in vitro as well as in vivo. We show that
wild-type p53 inhibits the ability of Z to mediate the switch
from latent to productive viral infection. Therefore, the pres-
ence of wild-type p53 protein in cells may tend to promote viral
latency.
MATERIALS AND METHODS
Cell lines. The cell lines used include the EBV-negative
Burkitt's lymphoma B-cell line Louckes, the latently infected
EBV-positive Burkitt's lymphoma B-cell lines Raji and Akata,
the cervical epithelial cell line HeLa (papillomavirus positive),
the primary human fibroblast cell line IMR-90, and the D98/
HE-R-1 cell line, which was formed by fusion of a HeLa cell
subclone (D98) with the EBV-positive Burkitt's lymphoma cell
line P3HR-1 (45). In addition, we used clonal cell lines derived
from either Akata cells stably transfected with a construct
containing wild-type p53 under the control of the inducible
metallothionein promoter or clones stably transfected with the
pMEP4 vector (Invitrogen) alone. The stably transfected
Akata cell lines (gifts from Paul Farrell) have been previously
described (66). All lymphoid cell lines were maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum.
All epithelial and fibroblast cell lines were maintained in
Dulbecco modified Eagle medium H supplemented with 10%
fetal calf serum.
Plasmids. (i) EBV transactivator plasmids. Construction of
the BRLF1 (R) and Z transactivating plasmids has been
previously described (25, 30, 49). The Z plasmid (pCMV-Z)
(30) contains the EBV Z cDNA (a gift from Alain Sergeant)
cloned into the pGEM2-based vector pHD1013 such that the Z
immediate-early gene is under the control of the strong
cytomegalovirus immediate-early (CMV IE) promoter. The R
plasmid (pEBV-RIE) contains the R immediate-early gene
(contained within a genomic EBV fragment) linked to the
CMV IE promoter in a pUC-based plasmid (25, 49).
(ii) EBV promoter plasmids. The BMRF1-CAT construct
(formerly referred to as EA-BS-CAT) has been previously
described (25) and contains the early EBV promoter BMRF1
sequences from -331 to + 1 (relative to the RNA start site)
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linked to the chloramphenicol acetyltransferase (CAT) gene in
the Bluescript SK+ phagemid vector (Stratagene). The
BHRF1-CAT construct contains the early EBV BHRF1 pro-
moter sequences (from -972 to +46 relative to the RNA start
site) linked to the CAT gene in the pBS-CAT vector (a gift
from Frank Funari).
(iii) Bacterial Z proteins. The glutathione S-transferase
(GST)-Z fusion protein contains the entire Z open reading
frame inserted in frame into the pGEX-3X vector (Pharmacia)
downstream of the GST protein. Three deletions of GST-Z,
removing either amino acids 25 to 86 (in frame) from the
transactivator domain (ZA25-86), amino acids 200 to 227 (in
frame) from the coiled-coil dimerization domain (ZA200-227),
or amino acids 0 to 143 (in frame), were also constructed.
(iv) p53 plasmid constructs. The p53 reporter construct,
pG13-CAT (a gift from Bert Vogelstein), has been previously
described (32) and contains 13 copies of the consensus p53
binding site upstream of the polyomavirus early promoter
linked to the CAT gene (32). The p53 transactivator plasmids,
pC53-SN3, pC53-SCX3, pC53-175, and pC53-248 (gifts from
Bert Vogelstein), have been previously described (2) and
contain either wild-type (pC53-SN3) p53 or p53 mutated at
amino acid 143 (pC53-SCX3), 175 (pC53-175), or 248 (pC53-
248) under the control of the CMV IE promoter. In addition,
the BamHI fragments (containing the p53 gene) of these
constructs were recloned into the pBS vector (Stratagene)
downstream of the T7 promoter. By using these new con-
structs, in vitro-translated wild-type (or mutant) p53 was
obtained by in vitro transcription with T7 polymerase, followed
by in vitro translation (in the presence of [ 5S]methionine) with
reticulocyte lysate (Promega). The mutant p53 proteins,
p53A375 and p53A345, were obtained by cutting the wild-type
p53 pBS construct with either AccI or SmaI prior to in vitro
transcription and translation.
DNA transfections. Plasmid DNA was purified through two
sequential cesium chloride gradients. DNA was transfected
into both lymphoid and epithelial cells by electroporation,
using 10 ,ug of DNA and 107 cells per condition. Cells were
shocked at 1,500 V with a Zapper electroporation unit (Med-
ical Electronics Shop, University of Wisconsin). Epithelial cells
were harvested and suspended in RPMI 1640 medium prior to
electroporation.
CAT assays. Cell extracts were prepared 48 h after transfec-
tion and incubated at 370C with [14C]chloramphenicol in the
presence of acetyl coenzyme A as described previously (21).
The percent acetylation of chloramphenicol was quantitated by
thin-layer chromatography followed by scintillation counting
or scanning with an AMBIS scanning densitometer (AMBIS,
Inc.).
Analysis of EBV termini. To distinguish latent versus pro-
ductive EBV infection, Southern blot analysis was used to
determine the state of the EBV termini (fused versus unfused).
Total cellular DNA was analyzed 3 days after transfection with
the Z transactivator plasmid by cutting with the enzyme
BamHI and probing with a 32P-labeled riboprobe spanning the
EBV sequences in the 1.9-kb XhoI fragment. As previously
described (50), this probe can be used to determine the relative
amount of EBV DNA containing fused versus unfused viral
termini. Unfused termini are observed only in the linear form
of the virus and are diagnostic of lytic infection.
Coimmunoprecipitation and Western blot (immunoblot)
analysis. Transfected Z and p53 proteins in CAT assays were
quantitated by Western blot analysis using monoclonal anti-
bodies directed against either the Z protein (antibody BZ.1
[73], a gift from Alan Rickinson, directed against the dimer-
ization domain of Z) or the p53 protein (antibody DO-1 [Santa
Cruz Biotechnology], directed against the amino-terminal por-
tion of p53). Analysis of BMRF1 induction in Akata cells was
done with monoclonal antibody 9240 (NEN/Dupont). Western
blot analysis was performed in phosphate-buffered saline
(PBS) with 5% powdered milk, using a 1:10 dilution of
monoclonal antibody BZ.1 or a 1:100 dilution of antibody
DO-1, followed by washing three times at room temperature
with 3% powdered milk-PBS and then addition of the second-
ary antibody (1:2,000 dilution of goat anti-mouse kappa-chain
horseradish peroxidase-conjugated serum (Southern Biotech-
nology Associates)). In certain experiments (Fig. 1D), pooled
sera from patients with nasopharyngeal carcinoma was used to
detect transfected Z protein. In some cases (Fig. 6B), Western
blotting was done with antibody DO-1 which had been directly
conjugated to horseradish peroxidase (to avoid cross-reaction
of the anti-mouse secondary antibody with the mouse mono-
clonal antibodies used in the immunoprecipitations). Immuno-
blotting was done by using enhanced chemiluminescence per-
formed as recommended by the manufacturer (Amersham Life
Sciences).
Coimmunoprecipitation experiments were performed 2 days
after transfection of D98/HE-R-1 cells with the Z or p53
expression vector or 1 day after anti-immunoglobulin G (IgG)-
cadmium chloride treatment of the Akata cell subclones. Cells
were rinsed with cold PBS, pelleted, frozen in dry ice, thawed,
and resuspended in 0.4 ml of buffer (50 mM Tris-150 mM
NaCl-0.5 mM EDTA-0.5% Nonidet P-40 [pH 8.0] supple-
mented with 1 mM phenylmethylsulfonyl fluoride and 1 ,uM
pepstatin [Boehringer Mannheim] protease inhibitors). The
cell lysate was then sonicated six times and pelleted again, and
equal amounts of protein supernatant (approximately 100 ,ug)
were incubated overnight at 4°C with 10 pJ of either p53-
specific antibody DO-1, Z-specific antibody BZ.1, or c-Myc
monoclonal antibody C-33 (Santa Cruz Biotechnology). Ex-
tracts were then immunoprecipitated with protein A-Sepha-
rose 4B beads (Sigma) and washed five times (at 4°C) in buffer
containing 20 mM N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid (HEPES; pH 7.7), 75 mM KCl, 0.1 mM EDTA,
25 mM MgCl2, 10 mM dithiothreitol, and 0.15% Nonidet P-40.
The immunoprecipitated proteins were separated on a sodium
dodecyl sulfate (SDS)-8% gel, transferred to nitrocellulose
paper, and analyzed by Western blot analysis using either
p53-specific antibody DO-1 or Z-specific antibody BZ.1 as
described above.
GST fusion protein affinity chromatography. The ability of
35S-labeled, in vitro-translated p53 proteins to interact with the
various GST-Z fusion proteins was analyzed by affinity chro-
matography as previously described (60, 69). Bacterial cultures
(50 ml) containing either the pGEX-3X vector or the various
GST-Z constructs were induced with isopropylthiogalactopyr-
anoside (IPTG), pelleted, resuspended in 5 ml of PBS, soni-
cated, and cleared of bacterial debris by centrifugation at
12,000 x g. For each condition, 100 [lI of the lysate was
incubated in 1 ml of PBS for 20 min at room temperature with
5 jil of glutathione-agarose beads (Sigma). The GST proteins
were purified by three cycles of centrifugation and washing in
1-ml aliquots of buffer containing 20 mM HEPES (pH 7.7), 75
mM KCl, 0.1 mM EDTA, 25 mM MgCl2, 10 mM dithiothreitol,
and 0.15% Nonidet P-40. The purified GST protein was then
incubated with 15 jil of 35S-labeled, in vitro-translated p53
protein in 1 ml of the wash buffer for 1 h at room temperature.
Bead complexes were washed five times in the buffer described
above, centrifuged, resuspended in Laemmli sample buffer,
and then analyzed by electrophoresis on SDS-8% polyacryl-
amide gels followed by autoradiography.
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FIG. 1. Cotransfection of p53 and Z results in inhibition of Z
transactivator function. (A and B) The effects of p53 upon Z-induced
transactivation of the early BMRF1 promoter (A) or the early BHRF1
promoter (B) were examined in the IMR-90 cell line (a primary human
fibroblast cell line containing wild-type p53) (A) or the D98/He-R-1
cell line (a fusion between HeLa cells and the EBV-positive Burkitt's
lymphoma cell line P3HR1) (B). The percent acetylation of 14C-
labeled chloramphenicol in each condition (measured as previously
described [211) is shown. Columns (left to right): 5 ,ug of the
promoter-CAT plasmid and 5 ,ug of pHD 1013 vector DNA (containing
the CMV IE promoter); 5 jLg of promoter-CAT plasmid, 5 ,ug of
pHD1013 vector, and 1 ,ug of the p53 wild-type (pS3wt) construct
RESULTS
p53 inhibits Z-dependent transactivation of early EBV
promoters. Initial experiments examined the effect of p53
protein upon Z transactivator function in cotransfection as-
says. Two different early EBV promoters (linked to the re-
porter CAT gene) containing previously defined Z-binding
sites were assayed for the ability to respond to the Z transac-
tivator in the presence or absence of overexpressed p53
protein. Overexpression of wild-type p53 in transient assays
significantly decreased the ability of Z to activate the EBV
early BMRF1 promoter (25, 49) (Fig. IA) or the early BHRF1
promoter (8) (Fig. iB). In contrast, p53 constructs containing
mutations at amino acid 143, 175, or 248 had little or no effect
(Fig. IA to C and data not shown). The inhibitory effect of p53
upon Z transactivator function was observed in a variety of cell
types, including HeLa and D98/HE-R-1 (both of which contain
essentially no endogenous p53 because of the presence of the
E6 papillomavirus protein, which degrades p53), Raji (which
contains mutant p53 [11]), and primary human lung fibroblasts
(IMR-90, which contain wild-type p53). The ability of the
BHRF1 promoter to respond to another EBV immediate-early
transactivator, R (8, 22, 24), was not significantly inhibited by
p53 (Fig. 1C). The inhibitory effect of p53 upon Z transacti-
vator function is unlikely to be an indirect result of p53 cell
cycle effects, since cotransfection of the Rb tumor suppressor
gene product (which produces similar effects upon the cell
cycle) did not reduce Z transactivator function (data not
shown). Furthermore, the levels of transfected Z protein
(determined by Western blot analysis) in the same extracts
used for determination of CAT activity were shown to be
similar in the presence and absence of cotransfected p53
protein (Fig. ID and 2C).
These data suggest that wild-type p53 protein inhibits Z-
induced (but not R-induced) transactivation of early EBV
promoters. The overexpression of p53 in cotransfection assays
has been previously shown to inhibit the activity of a wide
(pC53-SN3) containing wild-type p53 cDNA under the control of the
CMV IE promoter (2); 5 ,ug of promoter-CAT construct, 5 ,ug of
pHD1()3 vector, and I ,ug of a p53 mutant (pS3mt) construct
(pC53-SCX3) mutated at amino acid 143 (2); 5 jLg of promoter-CAT
construct and 5 ,ug of the Z expression vector (pCMV-Z) containing
the Z cDNA in the pHD1013 vector; 5 ,ug of promoter-CAT plasmid,
5 ,ug of pCMV-Z, and 1 pg of wild-type p53 plasmid; 5 pug of
promoter-CAT plasmid, 5 ,ug of pCMV-Z, and 1 jig of mutant p53
construct. (C) The effects of wild-type versus mutant p53 upon
transactivation of the early BHRF1 promoter by two different EBV
immediate-early transactivators were compared in HeLa cells by using
CAT assays (21). Fold transactivation of BHRFI promoter activity is
shown. Columns (left to right): 5 ,ug of the Z transactivator construct,
pCMV-Z, versus equal amounts of pHDI013 vector DNA; 5 ,ug of
pCMV-Z and 1 ,ug of wild-type p53 expression plasmid, pC53-SN3; 5
,ug pCMV-Z and 1 ,ug of p53 plasmid (pC53-SCX3) mutated at amino
acid 143; 5 ,ug of the R expression vector, pEBV-RIE, which contains
the EBV R transactivator protein in the pHD1013 vector; 5 ,ug of the
pEBV-RIE vector and 1 ,ug of wild-type p53 plasmid. (D) The level of
transfected Z protein (driven by the CMV IE promoter) was deter-
mined by Western blot analysis. D98/HE-R-1 cells were transfected
with either the BHRFI-CAT plasmid and pHD1013 vector DNA (lane
1), BHRF1-CAT and pCMV-Z (lane 2), BHRF1-CAT and pCMV-Z
plus wild-type p53 plasmid (lane 3), or BHRFI-CAT and pCMV-Z
plus mutant p53 (lane 4). Z-induced transactivation of the early
BHRF1 promoter in the same extracts (determined by CAT assay) was
inhibited 80% by the presence of transfected wild-type (but not
mutant) p53 protein (data not shown). Cotransfection of p53 protein
did not significantly reduce the expression of transfected Z protein.
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FIG. 2. Z inhibits p53-dependent transactivation. (A) Five micro-
grams of the pG13-CAT construct, which contains 13 copies of the
p53-binding motif inserted upstream of the polyomavirus early pro-
moter, was transfected into either Louckes cells (an EBV-negative
Burkitt's lymphoma with mutant p53 [11]) or Raji cells (an EBV-
positive Burkitt's lymphoma with mutant p53 [11]) with 1 ,ug of the p53
expression plasmid and 5 jg of the pHD1013 vector (p53wt), with 5 jig
of the Z expression plasmid (Z), or with 1 ,ug of the p53 expression
plasmid and 5 jig of the Z expression vector (Z + p53wt). Results are
expressed as fold activation of the pG13-CAT construct relative to
vector DNA alone. The level of p53-dependent transactivation was
decreased in the presence of the Z gene product. (B) The ability of a
series of Z mutants to inhibit p53-dependent transactivation was
assessed in Raji cells. Columns (left to right): 5 ,ug of the pG13-CAT
plasmid with 1 jig of the p53 expression construct and 5 jig of
pHD1013 vector DNA; 1 jig of p53 plasmid and 5 jig of pCMV-Z
DNA; 1 jig of the p53 expression plasmid and 5 jig of the Z311
plasmid; 1 jig of the p53 plasmid and 5 jig of ZA29-42; 1 jig of the p53
plasmid and 5 jig of ZA200-227. The mutant Z plasmids were
constructed as previously described (30) except that they have been
inserted into the pHD1013 vector. The Z311 construct contains a point
mutation in the basic domain which inhibits DNA binding, the
ZA29-42 plasmid is deleted of amino acids 29 to 42 within the Z
transactivator domain, and the ZA200-227 plasmid is deleted of amino
acids 200 to 227 in the coiled-coil dimerization domain (30). The
results are expressed as the percent of p53-induced transactivation
relative to the effect of p53 plus vector DNA, which produced an
average 140-fold activation in this set of experiments. (C) The level of
transfected p53 protein in the presence and absence of cotransfected Z
was assessed by Western blot analysis in the IMR-90 cell line (which
contains endogenous wild-type p53). Lanes: 1, 5 jig of pHD1O13
vector; 2, 1 jig of wild-type p53 plasmid and 5 jig of pHD1O13 vector;
3, 5 jig of Z expression plasmid; 4, 1 jig of wild-type p53 and 5 jig of
Z expression plasmid. Expression of transfected p53 was assessed by
variety of promoters (20), perhaps by inhibition of the TATA-
binding protein (TBP) (56). However, our finding that Z-
dependent transactivation is much more sensitive to inhibition
by p53 than R-dependent transactivation suggested that p53
inhibition of Z function might be due to a specific interaction
between Z and p53.
Z inhibits p53-dependent transactivation. The p53 protein is
a sequence-specific DNA-binding protein and transcriptional
transactivator (10, 16, 27, 31, 32, 51, 57). Recently, two viral
proteins known to interact directly with p53 (the papillomavi-
rus E6 protein and the adenovirus Elb protein) have been
shown to inhibit p53-mediated effects in cotransfection assays
(36, 72). If the Z and p53 proteins can also interact directly in
vivo, then cotransfection of Z with p53 might likewise be
expected to inhibit p53-dependent transactivation. As shown in
Fig. 2, this is indeed the case. Cotransfection of the wild-type
Z construct with the p53 vector significantly reduced p53-
dependent transactivation in either Louckes cells (an EBV-
negative Burkitt's lymphoma line) or Raji cells (an EBV-
positive Burkitt's lymphoma line) (Fig. 2A). Both of these cell
lines contain mutant p53 (11). Similar results were obtained in
the primary human fibroblast cell line IMR-90, containing
wild-type p53 (data not shown). Furthermore, the level of
transfected p53 protein was assessed by Western blot analysis
in IMR-90 cells and shown to be somewhat increased after
cotransfection with Z (Fig. 2C). Therefore, inhibition of p53
transactivator function by Z cannot be due to decreased
expression of p53.
Inhibition of p53 transactivation was also observed with use
of mutant Z constructs in which either the DNA-binding
function of Z had been abolished (plasmid Z31 1, containing a
point mutation in the basic DNA-binding domain [30]) or the
transactivator function had been inhibited (plasmid ZA29-42
[30]) (Fig. 2B). The ZA200-227 construct, in which the coiled-
coiled dimerization domain of Z had been deleted, no longer
inhibited p53 function. However, since this last mutant (in
contrast to the other two mutants) does not produce stable
nuclear Z protein (30), the failure of this mutant to inhibit p53
function is not necessarily due to the loss of the dimerization
domain.
p53 inhibits disruption of EBV latency. To study the p53-Z
interaction in a more biologically relevant context, we next
examined the effect of p53 overexpression in EBV-infected
cells. Transfection of Z into latently infected cells is sufficient
to induce disruption of viral latency (6, 52, 62). Lytically
infected cells contain the productive, linear form of EBV as
well as the episomal form (33). Restriction cutting with the
enzyme BamHI causes the linear form of the virus to appear as
a ladder in gel electrophoresis as a result of the different
number of terminal repeats present in each replicated virus
(50). In latent EBV infection, the virus forms an episome
(produced by fusion of the terminal repeats), and only one size
restriction fragment is observed (50).
The Z-induced switch from latent to lytic EBV infection was
examined by Southern blot and Western blot analysis (Fig. 3).
As expected, with the induction of lytic viral replication, an
increase in both the fused-termini form of virus (representing
the formation of newly replicated head-to-tail concatemers
which have not yet been cleaved) and the ladder form (repre-
senting the cleaved linear form of the virus) was observed (Fig.
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FIG. 3. The disruption of viral latency by Z is inhibited by p53
overexpression. (a) Latently infected D98/HE-R-1 cells were trans-
fected with 5 ,ug of pHD1013 vector DNA (lane C), 5 ,ug of pCMV-Z
plasmid DNA (lane D), or 5 jig of pCMV-Z plus 10 jig of wild-type
p53 DNA (lane E). Lane A contains DNA from B95-8 cells (TPA-
sodium butyrate induced) to serve as the positive control for lytic EBV
infection, and lane B contains DNA from the EBV-negative B-cell line
Louckes. Cellular DNA was analyzed 3 days after transfection by
cutting with the enzyme BamHI and probing with a 32P-labeled
riboprobe spanning the EBV sequences in the 1.9-kb XhoI fragment.
As previously described (50), this probe can be used to determine the
amount of EBV DNA containing unfused (linear) viral termini. The
linear form of EBV is observed in productive (but not latent) EBV
infection. The amounts of transfected plasmid DNA were determined
by Southern blotting and shown to be equal in the presence and
absence of cotransfected p53 (data not shown). The increase in the
fused form of EBV observed during Z-induced lytic infection is due to
the formation of head-to-tail concatemers which have not yet been
cleaved. (b) The ability of transfected Z plasmid to disrupt viral latency
in D98/HE-R-1 cells in the presence and absence of cotransfected p53
was analyzed by the Western blot procedure. Lanes: 1, 5 ,ug of
pHD1013 vector DNA; 2, 5 ,ug of Z expression plasmid; 3, 5 ,ug of
pHD1013 vector and 3 jig of wild-type p53 plasmid; 4, 5 jig of
pHD1013 vector and 3 jig of mutant p53 plasmid; 5, 5 jig of Z
expression vector and 3 jig of wild-type p53 plasmid. Expression of the
EA-D complex in the transfected cells was quantitated by using
monoclonal antibody NEA-9240 (top), and expression of the Z protein
was quantitated by using monoclonal antibody BZ.1 (bottom). The
ability of transfected Z to induce expression of early protein was
inhibited by cotransfection with wild-type p53, even though the level of
transfected Z protein was not significantly reduced. Expression of
mutant p53 alone is not sufficient to disrupt latency.
3a). The ability of transfected Z protein to disrupt viral latency
in D98/HE-R-1 cells was diminished in the presence of co-
transfected p53 protein. In contrast, overexpression of p53 in
latently infected cells did not affect the level of episomal viral
DNA. The amounts of transfected plasmid DNA (determined
by Southern blot analysis) were also similar in the presence and
absence of cotransfected p53 (data not shown).
Similarly, when the ability of transfected Z to induce expres-
sion of early EBV proteins was analyzed by Western blot
analysis (Fig. 3b), the presence of cotransfected p53 signifi-
cantly reduced the ability of Z to induce expression of the EBV
early antigen-diffuse (EA-D) complex (BMRF1), although the
levels of transfected Z protein were similar in the presence and
absence of cotransfected p53. These results suggest that over-
expression of wild-type p53 may promote viral latency by
inhibiting the ability of Z to induce lytic replication.
Z and p53 interact directly in vitro. To determine whether
the Z and p53 proteins can interact directly in vitro, the ability
of a Z-GST fusion protein to interact with in vitro-translated,
35S-labeled p53 was investigated by affinity chromatography
(Fig. 4). The intact 245-amino-acid Z protein (linked to GST)
retained labeled p53 protein to glutathione-linked beads,
whereas the beads alone or the beads coated with GST protein
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FIG. 4. A GST-Z fusion protein retains labeled p53 protein in
affinity chromatography assays. The entire 245-amino-acid Z open
reading frame was inserted into the pGEX-3X vector (Pharmacia)
downstream of the GST protein to create the GST-Z fusion protein.
Three deletions of GST-Z, removing either the transactivator domain
(ZA25-86), the first 143 amino acids of Z (ZAO-143), or the coiled-coil
dimerization domain (ZA200-227), were also constructed. The ability
of these GST-Z fusion proteins to interact with 35S-labeled, in vitro-
translated p53 protein was evaluated in affinity chromatography stud-
ies using glutathione-linked beads. (A) Retention of the labeled
wild-type p53 protein (pS3WT) or mutant p53 proteins (p53A375,
p53A345, p53*175, and p53*248) by the various GST columns is
shown. The p53A375 and p53A1345 constructs are truncated at amino
acids 375 (removing the last 18 amino acids of p53) and 345 (removing
the last 48 amino acids), respectively, whereas the p53*175 and
p53*248 constructs contain point mutations in the amino acids indi-
cated. The size of full-length in vitro-translated p53 is indicated by the
arrow (the smaller bands represent degradation products). Lanes: 1 to
5, input wild-type and mutant p53 proteins; 6 to 15, retention of the
wild-type versus mutant p53 proteins by the GST protein alone versus
the intact GST-Z fusion protein. (B) Retention of the wild-type p53
protein by the GST protein alone (lane 2), the intact GST-Z protein
(lane 3), or the GST-Z proteins deleted in the transactivator domain
(lane 4), the coiled-coil dimerization domain (lane 5), or the amino-
terminal half (lane 6).
did not retain p53 (Fig. 4A, lanes 6 and 7). Removal of the final
18 amino acids from the 393-amino-acid p53 protein
(p53A375) significantly reduced the interaction between Z and
p53 (lanes 8 and 9), and removal of the last 48 amino acids of
p53 (p53A345) totally abolished the interaction (lanes 10 and
11). Three mutant forms of p53 commonly observed in human
tumors (26) (containing point mutations in amino acids 143,
175, and 248) were still capable of interacting with the GST-Z
protein in this assay (lanes 12 to 15, and data not shown), even
though none of these mutant forms of p53 could inhibit Z
transactivation in vivo (Fig. 1A and data not shown). Mutant
forms of the GST-Z protein in which the transactivator domain
of Z (which is required for interaction of Z with TBP [40]) had
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been deleted were still able to interact with p53 (Fig. 4B, lanes
4 and 6), whereas a mutation which removed the coiled-coil
dimerization domain of Z (amino acids 200 to 227) eliminated
interaction with p53 (lane 5). The carboxy-terminal portion of
Z (which contains the dimerization domain) was sufficient for
interaction with p53 in vitro (lane 6). Therefore, interaction
between Z and p53 appears to require the coiled-coiled
dimerization domain of Z and the carboxy-terminal portion of
p53.
Transfected Z and p53 proteins interact directly in vivo. The
results presented above strongly suggested that the Z and p53
proteins can interact through direct protein-protein interac-
tions. However, in vitro experiments may utilize conditions for
protein-protein interactions which are not physiologic. There-
fore, we also examined whether Z and p53 can directly interact
in vivo. As shown in Fig. 5A, in D98/HE-R-1 cells cotrans-
fected with the Z and p53 expression vectors, immunoprecipi-
tation with the p53-specific antibody (but not a control mono-
clonal antibody) precipitated not only the p53 protein but also
the Z protein. The Z protein was not precipitated by the p53
antibody in the absence of cotransfected p53. In the reverse
experiment (Fig. Sb), immunoprecipitation with the Z-specific
antibody (but not the control antibody) precipitated not only
the Z protein but also the p53 protein. In both types of
experiments, the wild-type p53 protein was shown to interact
much more strongly with Z than did the p53 protein mutated
at amino acid 143. Thus, although the results from the in vitro
GST fusion protein precipitation experiments (Fig. 4) could
not distinguish between the ability of Z to interact with
wild-type versus mutant p53, Z clearly interacted more effi-
ciently in vivo with the wild-type protein. The discrepancy in
the results obtained by these two different methods suggests
either that a cellular protein (not present in reticulocyte
extracts) can stabilize the interaction between Z and wild-type
(but not mutant) p53 in vivo or that the GST fusion protein
method may allow for stabilization of the weaker protein-
protein interaction between Z and the mutant p53 proteins.
Interestingly, as shown in Fig. SB, we repeatedly found that
cotransfection of Z with the p53 expression plasmids into
D98/H-R-1 cells dramatically increased the level of transfected
wild-type p53 protein and, to a much lesser extent, also
increased the level of p53 mutated at amino acid 143. The
ability of cotransfected Z to increase the level of wild-type p53
protein to a greater extent than mutant p53 in D98/HE-R1
cells suggests that the interaction between Z and p53 may
prevent the p53 degradation induced by the papillomavirus E6
protein in this cell line (a fusion between HeLa and P3HR1
cells).
Expression of wild-type p53 in Akata cells inhibits anti-IgG-
induced disruption of viral latency. To further confirm that
expression of wild-type p53 inhibits disruption of viral latency,
we examined the effect of anti-IgG treatment in Akata cell
subclones (66) which have been stably transfected with either
an inducible p53 expression vector (under the control of the
metallothionein promoter) or the same vector without p53.
The Burkitt's lymphoma Akata line, which normally produces
no p53 protein (66), contains EBV in a tightly latent state but
can be efficiently induced into lytic infection by treatment with
anti-IgG (58). Anti-IgG treatment in Akata cells activates
transcription of the BZLF1 promoter (58), and Z subsequently
activates expression of the early EBV promoters.
As shown in Fig. 6A, Akata cells stably transfected with p53
under the control of the metallothionein promoter constitu-
tively express a small amount of p53, which is vastly increased
after cadmium chloride treatment. Akata cells stably trans-
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FIG. 5. Cotransfected Z and p53 can be coimmunoprecipitated in
vivo. D98/HE-R-1 cells were transfected with either the pHD1013
vector (lane 1), the Z expression plasmid pCMV-Z (lane 2), the p53
expression plasmid mutated at amino acid 143, pC53-SCX3 (lane 3),
the wild-type p53 expression plasmid pC53-SN3 (lane 4), the Z and
mutant p53 expression plasmids together (lane 5), or the Z and
wild-type p53 expression plasmids together (lane 6). Whole cell
extracts were harvested 2 days after transfection, and equal amounts of
protein from each condition were incubated with an antibody (Ab)
directed against either the Z protein (BZ.1), the p53 protein (DO-1),
or the EBV early BMRF1 protein (9240). Extracts were then immu-
noprecipitated with protein A-Sepharose 4B beads, separated by
SDS-polyacrylamide gel electrophoresis, transferred to a nitrocellulose
filter, and analyzed by Western blotting with antibody BZ.1 (A) or
DO-1 (B) for the presence of Z and p53 proteins. (A) The amounts of
Z protein in extracts immunoprecipitated with either the p53-specific
antibody (top) or the BMRF1-specific control antibody (middle) were
compared in the presence and absence of cotransfected p53 protein.
The bottom panel shows the protein directly loaded onto the gel. Z
protein was coimmunoprecipitated with the p53 antibody (but not the
control antibody) in the presence of cotransfected p53 protein. Wild-
type p53 coimmunoprecipitated the Z protein more efficiently than did
mutant p53 protein in two separate experiments. (B) The amounts of
p53 protein in extracts immunoprecipitated with either the Z-specific
antibody (top) or the control antibody (middle) were compared in the
presence and absence of cotransfected Z protein. The bottom panel
shows protein directly loaded onto the gel. Wild-type p53 protein was
coimmunoprecipitated with Z protein more efficiently than mutant p53
in two separate experiments. Cotransfection of Z in the D98/HE-R-1
cell line consistently increased expression of transfected wild-type p53
to a greater extent than mutant p53.
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FIG. 6. Induction of p53 expression in stably transfected Akata
cells inhibits anti-IgG-mediated disruption of viral latency. (A) The
disruption of EBV latency in Akata cells stably transfected with either
the pMEP4 vector (containing the inducible metallothionein pro-
moter; Invitrogen) alone (lanes 1 and 2) or the p53 wild-type cDNA in
the pMEP4 vector (lanes 3 to 6) was compared by Western blot
analysis in the presence and absence of anti-IgG treatment (to induce
Z expression) or the presence and absence of cadmium chloride (to
induce p53 expression). The Akata Burkitt's lymphoma line normally
contains no p53 (since both alleles are mutated [66]). Protein extracts
were harvested after 12 h of anti-IgG treatment and 8 h of cadmium
chloride treatment (begun 4 h after anti-IgG treatment). Expression of
p53 was quantitated by using antibody DO-1 (top), expression of Z was
quantitated by using antibody BZ.1 (middle), and expression of the
EA-D complex was quantitated by using antibody 9240 (bottom). The
p53-transfected cell line expresses small amounts of p53 protein
constitutively and much greater amounts of p53 after cadmium chlo-
ride treatment. The level of Z expression induced by anti-IgG treat-
ment was not affected by the presence or absence of p53. However, the
induction of early protein expression was inhibited by p53. (B)
Coimmunoprecipitation experiments were performed to confirm that
Z and p53 interact in vivo in the Akata cell line stably transfected with
the inducible p53 expression vector. Extracts from uninduced cells
(lanes 3 and 10 to 12), cells induced to express both Z and p53 with
anti-IgG antibody and cadmium chloride treatment (lanes 2 and 7 to
9), or cells induced to express p53 alone (with cadmium chloride
treatment) (lanes 1 and 4 to 6) were either directly loaded onto the gel
(lanes 1 to 3) or immunoprecipitated with mouse monoclonal antibod-
ies directed against p53 (DO-1), EA-D (9240), or Z (BZ.1). The
amount of p53 protein immunoprecipitated with each antibody was
determined by Western blot analysis using the DO-i antibody. The Z
antibody coimmunoprecipitated p53 only when both Z and p53 were
present in the cellular extracts.
Anti-IgG treatment of the cells containing either vector DNA
or the p53 expression vector (in the presence or absence of
cadmium chloride induction) induced expression of equivalent
amounts of Z protein, indicating that the presence of p53 does
not affect the ability of anti-IgG to activate Z transcription.
However, the ability of Z to induce expression of the EA-D
complex was significantly decreased even by the small amounts
of constitutive p53 expression found in the uninduced p53 cell
line and was further decreased by the induction of p53
expression after cadmium chloride treatment. Therefore, the
presence or absence of wild-type p53 can significantly alter the
ability of Z to disrupt viral latency.
Z and p53 also interact directly in Burkitt's lymphoma cells
stably transfected with the inducible p53 expression vector. To
confirm the importance of the in vivo interaction between Z
and p53, we ideally would demonstrate that the two proteins
can be coimmunoprecipitated from nontransfected cells. How-
ever, since the experiments in transfected cells indicate that Z
interacts efficiently in vivo only with wild-type (not mutant)
p53, the ability to coimmunoprecipitate Z and p53 in nontrans-
fected cells requires a cell line expressing reasonable levels of
both Z and wild-type p53. After screening a variety of EBV-
positive cell lines, we were unable to find any naturally
occurring lines expressing high levels of both wild-type p53 and
Z. We therefore performed coimmunoprecipitation experi-
ments in the stably transfected Akata subclones described
above to determine whether an in vivo interaction between Z
and p53 could be demonstrated in this cell line. The Akata cell
lines were induced with either anti-IgG antibody as previously
described (58) for 12 h, cadmium chloride (at 5 p,M, added 4
h after the start of anti-IgG treatment), or both anti-IgG and
cadmium chloride. As shown in Fig. 6B, in the cells induced
with cadmium chloride and anti-IgG to express both p53 and
Z, immunoprecipitation with a Z-specific antibody coimmuno-
precipitated the p53 protein. In cells induced with cadmium
chloride alone, the Z antibody did not coimmunoprecipitate
p53, showing that Z and p53 must both be present in the
extract for coimmunoprecipitation to occur. These results
indicate that Z and p53 can interact directly in vivo in cells
which have been stably transfected with an inducible p53
expression vector.
DISCUSSION
In this report, we have shown that an immediate-early EBV
protein which plays an essential role in the switch from latent
to lytic infection can interact directly with p53. The interaction
between Z and p53 in vitro appears to require the carboxy-
terminal portion of p53 and the dimerization domain of Z. In
vivo, the Z-p53 interaction results in inhibition of both the Z
and p53 transactivator functions. Our results suggest that one
of the cellular determinants promoting EBV latency may be
expression of the wild-type p53 tumor suppressor protein.
In EBV-infected B cells, the maintenance of viral latency is
of paramount importance to cell survival, since Z-mediated
activation of early EBV promoters is likely to lead to lysis and
death of the host cell. The regulation of viral latency in B cells
occurs through at least two different mechanisms. One level of
regulation involves the transcriptional control of the two
promoters driving Z gene expression (43). Both of these
promoters are normally silent in B cells (29, 74) but can be
activated by tetradecanoyl phorbol acetate (TPA) (15), anti-
IgG (58), or the Z protein itself (14, 64). However, since the Z
gene product can positively regulate its own transcription, even
small amounts of spurious Z gene transcription might be
expected to irreversibly activate the lytic cycle if there were not
additional negative control mechanisms. In keeping with this
notion, we have recently shown that the efficiency of Z
transactivator function (even when driven by a heterologus
promoter which functions well in all cell types) is very cell type
specific (25, 49). These data suggest that in addition to the
transcriptional regulation of the Z promoters, the efficiency of
Z transactivator function itself can also be regulated in a
cell-type-specific fashion.
Recently, we and others have found that Z interacts with a
number of viral and cellular proteins. In addition to interacting
with p53, Z can also interact directly with retinoic acid
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and several viral proteins (17, 28). The interaction of Z with
the p65 protein or the retinoic acid receptors results in
decreased Z function (23, 59). In contrast, we have shown that
the c-myb gene product can activate Z transactivator function
(30), apparently through an indirect mechanism. We have not
totally excluded the possibility that the interaction between Z
and p53 is mediated through one of these other proteins, since
each of the assays used to examine protein-protein interactions
included either reticulocyte lysate or cellular extracts. How-
ever, it is unlikely that interaction between Z and p53 is
mediated through TBP, since TBP interacts with the transac-
tivator domain of Z (40), whereas this region is dispensable for
the interaction between Z and p53.
Although the wild-type p53 protein inhibits the activity of
numerous different cellular and viral promoters (20), the
mechanism of p53 inhibition has not been well defined.
Recently, p53 has been shown to directly interact with several
cellular proteins, including TBP (56), a CCAAT box-binding
protein (1), Wtl (42), and Spl (4). The inhibition of TBP
function may explain the ability of p53 to downregulate
numerous different promoters. Our finding that the interaction
of p53 with Z is mediated through the coiled-coil dimerization
domain of Z suggests yet another mechanism by which p53
could potentially downregulate the activity of promoters, since
numerous cellular transcription factors (including c-Fos and
c-Jun) contain similar dimerization domains.
Although the carboxy-terminal portion of p53 is rarely
involved in spontaneous tumor mutations (26), this domain of
p53 has now been shown to be required for interaction with
TBP, the hsc-70 protein, and Z (48). In addition, the carboxy-
terminal portion of the protein, which contains two phosphor-
ylation sites, is required for oligomerization of p53, DNA
binding, and transformation of cells (48, 65). The Z protein, by
directly interacting with this critical domain of p53, could
potentially affect any of these p53 functions.
What is the biologic significance of the Z-p53 interaction?
Our finding that the Z protein can inhibit p53-dependent
transactivation suggests that overexpression of Z in EBV-
positive tumors could potentially play a role in tumor forma-
tion. However, the Z protein is generally not expressed in
EBV-positive Burkitt's lymphomas in vivo or in latently in-
fected (but immortalized) B-cell lines in vitro (33, 44). There-
fore, it is difficult to envision that inactivation of p53 function
by Z contributes to EBV-associated transformation in Burkitt's
lymphoma or is required for immortalization of primary B
cells.
In contrast, immunocompromised patients (in particular
organ transplant recipients and patients with AIDS) have a
high frequency of EBV-associated lymphomas, and in these
patients, up to 60% of EBV-positive lymphomas contain cells
expressing the Z protein (46). Z is also expressed in a small
percentage of nasopharyngeal carcinoma cells (7) and in
Reed-Sternberg cells of EBV-positive Hodgkin's disease (47).
The abortive expression of viral early antigens during impaired
cellular immunity could potentially provide a setting in which
the inhibition of p53 function by Z can complement the
transforming functions of the latent EBV gene products.
Although EBV-positive Burkitt's lymphomas (which are la-
tently infected in vivo and do not express Z) commonly contain
mutated p53 (11, 18, 71), other types of EBV-containing
malignancies (including nasopharyngeal carcinomas and EBV-
associated lymphomas in immunocompromised hosts) gener-
ally contain wild-type p53 (9, 49a). Nevertheless, the expres-
sion of Z protein in lymphomas and nasopharyngeal carcinoma
may simply reflect the immunocompromised state of these
patients, and there is currently no other evidence that this
protein contributes to the development of malignancy in vivo.
Alternatively, the interaction of Z with p53 may provide a
mechanism for regulating viral replication. Wild-type p53, by
functioning as a negative regulator of cell growth, may function
indirectly as an inhibitor of lytic viral replication by decreasing
the available pool of deoxypyrimidine nucleotides required for
viral synthesis (37). The results of this study suggest that in
addition to the indirect effects upon cell growth, wild-type p53
can also directly downregulate Z transactivator function
through a direct protein-protein interaction between Z and
p53. The biological consequence of the Z-p53 interaction is
likely to depend on the relative amounts of the two proteins
present in the cell. In latently infected cells, in which the level
of p53 protein would be expected to greatly exceed that of Z
(since Z is minimally transcribed during latency), wild-type p53
may inhibit the ability of small amounts of spuriously tran-
scribed Z protein to irreversibly activate the lytic viral cycle.
During disruption of viral latency (as occurs when transcription
of Z is activated), the level of Z protein would be expected to
exceed that of p53. In this case, inhibition of p53 function by Z
might ameliorate the inhibitory effect of p53 upon viral repli-
cation.
Z may not be the only EBV-encoded protein which interacts
directly with p53. Another group has recently reported that the
EBV leader protein, which is expressed during latent viral
infection, can also be coimmunoprecipitated with the p53
tumor suppressor protein (61). As yet, no data have been
published regarding the possible functional consequences of
this interaction, and it is unknown whether the EBV leader
protein, like Z, can inhibit p53-dependent transactivation. The
necessity for two different virally encoded proteins which
interact with p53 may reflect the fact that EBV uses separate
origins of replication during latent versus productive infection.
It is possible that the interaction between the leader protein
and p53 mediates viral replication during latent infection
(through the ori-P origin), whereas the interaction between Z
and p53 modulates replication during productive infection
(through the ori-Lyt origin).
It has been hypothesized that the interaction of papilloma-
virus, simian virus 40, and adenovirus with p53 serves to
promote cell growth and thereby enhance viral replication
(37). That EBV also encodes proteins targeting p53 suggests
that inactivation of p53 function may be a common require-
ment for the replication of many types of DNA viruses. We
have demonstrated that Z and p53 interact in vitro and in vivo
and that this interaction may inhibit the ability of Z to disrupt
viral latency. We are currently pursuing further experiments to
determine whether p53 status does indeed influence the strin-
gency of EBV latency.
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